complement factor I
آخر تحديث 18 Aug 2020
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال CFI gene provides instructions for making a protein called complement factor I. This protein helps regulate a part of the body's immune response known as the complement system. The complement system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. This system must be carefully regulated so it targets only unwanted materials and does not attack the body's healthy cells. Complement factor I and several related proteins protect healthy cells by preventing activation of the complement system when it is not needed.
Normal function
ال CFI gene provides instructions for making a protein called complement factor I. This protein helps regulate a part of the body's immune response known as the complement system. The complement system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. This system must be carefully regulated so it targets only unwanted materials and does not attack the body's healthy cells. Complement factor I and several related proteins protect healthy cells by preventing activation of the complement system when it is not needed.
Conditions referring to this gene or chromosome
Other names
AHUS3
C3b-INA
C3b-inactivator
C3B/C4B inactivator
C3BINA
CFAI_HUMAN
complement component I
complement control protein factor I
complement factor I heavy chain
complement factor I preproprotein
FI
IF
KAF
Konglutinogen-activating factor
light chain of factor I
Related patient information and medicines
Patient information leaflet
مضادات التخثر
In 2021, the UK's National Institute for Health and Care Excellence (NICE) recommended that DOACs should be the preferred option for AF, instead of warfarin. There are 13 known clotting factors which are called by their Roman numbers - factor I to factor XIII. ...ing factors, called the clotting cascade, quickly occursThe final step of this.
Patient information leaflet
نقص فيتامين ب12 وفقر الدم الخبيث
What causes vitamin B12 deficiency. Pernicious anaemia Normally, when you eat foods with vitamin B12, the vitamin combines with a protein called intrinsic factor in the stomach. Intrinsic factor is essential to absorb vitamin b12 into the body. Symptoms may get worse initially during treatment... How much vitamin B12 do I need per day to avoid.
Patient information leaflet
التهاب المفاصل الروماتويدي
Joint damage develops gradually, but the speed at which damage develops varies from person to person. A one-off pneumococcal immunisation if you are over the age of 65 years, or are taking immunosuppressive medicines, or are taking steroids equivalent to 20 mg or more of prednisolone each day for more than a month. Other treatments Some people try.
Patient information leaflet
اختبارات تخثر الدم
اختبارات تخثر الدم are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you h... These chemicals then react with other chemicals and proteins in the plasma, called clotting factors. There are 13 known clotting factors which.
Patient information leaflet
الهيموفيليا
الهيموفيليا is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.
Patient information leaflet
هل يمكنني تناول أبيكسابان وبيسوبرولول معًا؟
There is no direct interaction between apixaban and bisoprolol. They work in different ways and do not interfere with how the body processes each other. Why this happens أبيكسابان هو anticoagulant (blood thinner) that works by blocking a clotting factor called Factor Xa. Bisoprolol is a beta-blocker that slows the heart rate and lowers blood.
قراءة إضافية ومراجع
- complement factor I; MedlinePlus, National Library of Medicine.
- Baracho GV, Nudelman V, Isaac L. Molecular characterization of homozygous hereditary factor I deficiency. Clin Exp Immunol. 2003 Feb;131(2):280-6. doi: 10.1046/j.1365-2249.2003.02077.x.
- Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet. 2009 Jan;17(1):100-4. doi: 10.1038/ejhg.2008.140. Epub 2008 Aug 6.
- Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2008 Jan;45(1):95-105. doi: 10.1016/j.molimm.2007.05.004. Epub 2007 Jun 26.
- Nilsson SC, Trouw LA, Renault N, Miteva MA, Genel F, Zelazko M, Marquart H, Muller K, Sjoholm AG, Truedsson L, Villoutreix BO, Blom AM. Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol. 2009 Jan;39(1):310-23. doi: 10.1002/eji.200838702.
- Ponce-Castro IM, Gonzalez-Rubio C, Delgado-Cervino EM, Abarrategui-Garrido C, Fontan G, Sanchez-Corral P, Lopez-Trascasa M. Molecular characterization of Complement Factor I deficiency in two Spanish families. Mol Immunol. 2008 May;45(10):2764-71. doi: 10.1016/j.molimm.2008.02.008. Epub 2008 Mar 28.
- Richard I. The genetic and molecular bases of monogenic disorders affecting proteolytic systems. J Med Genet. 2005 Jul;42(7):529-39. doi: 10.1136/jmg.2004.028118.
- Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grunfeld JP, Lesavre P, Noel LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007 Mar;44(3):193-9. doi: 10.1136/jmg.2006.045328. Epub 2006 Oct 3.
- Vyse TJ, Morley BJ, Bartok I, Theodoridis EL, Davies KA, Webster AD, Walport MJ. The molecular basis of hereditary complement factor I deficiency. J Clin Invest. 1996 Feb 15;97(4):925-33. doi: 10.1172/JCI118515.
- Vyse TJ, Spath PJ, Davies KA, Morley BJ, Philippe P, Athanassiou P, Giles CM, Walport MJ. Hereditary complement factor I deficiency. QJM. 1994 Jul;87(7):385-401.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
18 Aug 2020 | أحدث إصدار
1 Sept 2010 | نُشر في الأصل
انضم إلى المحادثة
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.